oronary artery stent implantation increases the safety of percutaneous coronary intervention (PCI) and decreases the occurrence of restenosis. However, the rate of occurrence of restenosis after stent implantation is about 20%. Most drug therapies using antithrombotic agents and various antiproliferative agents are ineffective. However, some systemic drugs are expected to demonstrate efficacy. For example, Kondo et al reported that neointimal hyperplasia was inhibited by the angiotensin-converting enzyme (ACE) inhibitor quinapril during the post-stenting follow-up phase, as determined by observation using intravascular ultrasound (IVUS). 1 Okumura et al also reported that the administration of ACE inhibitors for the attenuation of lumen loss after coronary stent implantation is best for subjects with the D allele of the ACE genotype. 2 Furthermore, the large-scale study CAPARES (Coronary AngioPlasty Amlodipine REStenosis Study) also reported that therapy with the long-acting calcium channel blocker (CCB) amlodipine starting 2 weeks before percutaneous transluminal coronary angioplasty (PTCA) including stent implantation did not reduce luminal loss, but that the incidence of repeat PTCA and composite major adverse clinical events were significantly reduced during the 4-month follow-up period after PTCA with amlodipine as compared with the placebo. 3 In the present study, we investigated and compared poststenting vascular response to amlodipine or quinapril in the follow-up phase by quantitative coronary angiography (QCA) and IVUS.
In group A and group Q, the stented lesions were observed and compared by QCA and IVUS immediately after stenting and in the follow-up phase. There were 32 patients (48 lesions) in group A and 31 patients (53 lesions) in group Q. IVUS was not performed in the severely restenotic lesions in the follow-up phase (7 and 13 lesions in group A and group Q, respectively) and in the lesions with severe calcification and kinking (10 and 12 lesions in group A and group Q, respectively). Some lesions immediately after stenting could not be detected, as there were the same portion in the follow-up phase (11 and 12 lesions in group A and group Q, respectively). It was possible to obtain clear IVUS findings up to the follow-up phase in 20 lesions and 16 lesions, respectively.
Administration of aspirin at 162 mg and of ticlopidine at 200 mg/day began several days before stenting in all cases and continued until the follow-up phase.
The mean age of patients in group A was 68.5±7.0 years and in group Q was 66.1±8.9 years. Although the patients in both groups had many coronary risk factors, there were no significant differences in such factors between the groups (Table 1) .
By ACC/AHA classification of lesions, many complex lesions assessed as B2 and C were noted in both groups. There were no differences between the groups in either the morphology of other lesions or the type of stent used (Table 2 ).
Methods

Determination of QCA Findings
The coronary angiography (CAG) before and immediately after stenting as well as those in the follow-up phase (after 3 and 6 months from stenting) were investigated and compared between the groups by the edge detection method using a computer-assisted CAG analysis system (Cathex Coronary Image Processor-310, Cathex Company, Tokyo, Japan). 4 The lengths of the lesions were calibrated with the image of 6-F guiding catheter. CAG were performed after administration of intracoronary isosorbide dinitrate. The single view was chosen that best isolated the target lesion before and immediately after stenting and in the follow-up phase.
The reference diameter, minimal lumen diameter (MLD) and length of lesion were determined, and percentage diameter stenosis (%DS), diameter gained by treatment (acute gain = post MLD -pre-MLD), luminal loss in the follow-up phase (late loss = post MLD -follow-up MLD), and luminal loss index in the follow-up phase (loss index = late loss/acute gain) were obtained. Restenosis was defined as %DS = 50.
Determination of IVUS Findings
IVUS observation was performed from the distal reference vessel to the proximal reference vessel by auto pullback (0.5 mm/s) using an echo catheter (3.5 F 20 MHz, Endosonoics™, Endosonics Company, Rancho Cordova, USA). The findings were recorded in CD and analyzed by In-Vision™ (Endosonics Company, Rancho Cordova, USA). Before the IVUS procedure, 1-1.5 mg of isosorbide dinitrate was administered into the coronary artery. The target lesions in the post-stenting and the follow-up phase were identified using the closest axial landmark (eg, small side branches or calcified deposits). The reproducibility and the accuracy of this system have been previously described. 5, 6 For analysis, measurement was conducted at 5 sites of the target lesion (#1; proximal reference vessel, #2; proximal portion of stent, #3; middle portion of stent, #4; distal portion of stent, #5; distal reference vessel). The vessel area (VA), stent area (SA) and lumen area (LA) in each site were determined, and the plaque area (PA = VA -LA) and neointimal area (NA = SA -LA) were calculated. The ratio of plaque area to vessel area (PA/VA × 100) was used as the rate of area stenosis (% area stenosis; %AS) (Fig 1) .
More than 2 cardiologists and a laboratory independently analyzed QCA and IVUS findings without any clinical information.
All results are indicated as means ± SD. For statistical analysis, Student's t-test, Mann -Whitney's U-test and ANOVA were used for comparison between the 2 groups. The incidence of restenosis was compared between the groups by 2 independent test and Fischer's exact probability test. The level of significance was set at <5% (p<0.05). We explained the efficacy of these drugs and the aims of the present study to each patient and obtained informed consent. This trial was performed according to declaration of Helsinki protocols.
Results
Major adverse coronary events (composite of death, urgent coronary artery bypass surgery, periprocedural myocardial infarction, abrupt closure, and stent thrombosis) did not occur in the 2 groups. The systolic and diastolic blood pressure (BP) in the both groups reduced during the study.
The systolic BP reduced from 140±13 mmHg to 132± 11 mmHg and from 142±12 mmHg to 136±9 mmHg in group A and group Q, respectively. The diastolic BP reduced from 85±9 mmHg to 80±9 mmHg and 86±7 mmHg to 81±9 mmHg in group A and group Q, respectively. There was no significant difference of the change of BP between the 2 groups. Comparison of QCA Results (Table 3) Although there was no significant difference between the 2 groups in reference diameter before the operation, the MLD was significantly larger and %DS and loss index significantly smaller in group A in the follow-up phase. The MLD in group A decreased from 2.74 mm immediately after stenting to 1.88 mm in 3 months follow-up phase and the reduction rate was 31.4%. The MLD in group Q decreased from 2.58 mm to 1.52 mm and the reduction rate was 41.1%. The reduction rate in group A was significantly lower than that in the group Q (p<0.0001).
Although the lesion and patient restenosis rate in group A tended to be lower than that in group Q, the difference between the groups was not significant. The target lesion revascularisation (TLR) was found in 5 lesions in group A (10.4%) and 9 lesions in group Q (17.0%), showing no significant difference.
Analysis of IVUS Results
There were no differences in either patient background factors or QCA data between the 2 groups of patients whose the lesions were observed by IVUS within 6 months after stenting. There was no significant difference between the average follow-up period in group A and group B (5.0±1.5 months and 4.7±1.5 months, respectively). Table 4 shows data on the proximal and distal reference vessels obtained by IVUS. Neither the LA nor the PA of the proximal reference vessel differed between the groups either immediately after stenting or in the follow-up phase.
Although there was no change in the LA of the distal reference vessel in group A, PA tended to increase in the follow-up phase. A decrease in LA and a tendency toward increase in PA were noted in the distal reference vessel in group Q in the follow-up phase. However, there was no statistically significant difference between groups A and Q. Table 5 shows the IVUS findings obtained from the stenting site. The VAs in the proximal, middle and distal portions of the stent that were captured by IVUS differed between the groups neither immediately after stenting nor in the follow-up phase. As observed by IVUS, SA demon- 
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strated no difference between the groups in any site either immediately after stenting or in the follow-up phase. Compared with group Q, NA that was found in each site was significantly smaller in group A in the follow-up phase. A marked difference between groups was observed in the middle and distal portions of the stent. The PAs in the proximal and middle portions of stent in the follow-up phase were significantly smaller in group A than in group Q. Although not to a significant extent, LAs in the middle and distal portions of stent were smaller in group Q than in group A. (Fig 2) The NA in the middle portion of stent in the follow-up phase was 1.2 mm 2 . (Fig 3) The NA in the middle portion of stent in the follow-up phase was 2.7 mm 2 .
Cases
IVUS Findings of a Case in Group A
IVUS Findings of a Case in Group Q
Discussion
Amlodipine is a CCB with antioxidant properties. The PREVENT (Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial) demonstrated that amlodipine has anti-atherosclerotic and plaque stabilization properties, but its effect on coronary artery lesions has not been clarified. 7 In this regard, the NORMALISE study (Norvasc for Regression of Manifest Atherosclerotic Lesions by Intravascular Sonographic Evaluation) is now being performed to compare IVUS findings. According to our QCA results, the MLD in group A in the follow-up phase was larger, while %DS and loss index were smaller in group A than in group Q. There have been several reports on the activity of an ACE inhibitor against the instent restenosis observed by QCA. Although these reports for the most part compared the ACE inhibitor with a placebo, Ribichini et al reported that the ACE inhibitor might increase the risk of in-stent restenosis. 8 Meurice et al also reported that the result obtained with an ACE inhibitor was poorer than that obtained with a control agent. 9 Many studies found no significant difference in restenosis rate between the ACE inhibitor and the control when %DS of 50% or more was defined as restenosis.
The values measured by IVUS pose a problem concerning reproducibility. However, as no difference was noted in SA, which serves as a clear mark of IVUS finding, either between the groups or between immediately after stenting and the follow-up phase, the stent strut form was assumed to have been maintained. There was no difference between the groups in effect on the natural course of changes in either the proximal or distal reference vessels outside of the stent in the follow-up phase. The LA in the middle and distal portion of the stent in the follow-up phase were smaller in group Q than in group A, although not to a significant extent. Compared with group A, the increase in NA in group Q was significantly larger in the middle and distal portions of the stent. The NAs in the 3 portions of the stent in group A were almost constant in the follow-up phase, suggesting appropriate intimal coating over the stent. Therefore, the larger MLD in group A captured by QCA seemed to be attributable to a smaller NA in IVUS compared with group Q. Many studies on the efficacy of drugs against in-stent restenosis were based on data obtained by QCA, and there are very few reported IVUS findings. The results of our study were endorsed by IVUS findings. A major cause of in-stent restenosis is neointimal hyperplasia, 10, 11 and amlodipine appeared to demonstrate stronger inhibition of neointimal hyperplasia than quinapril. However, in comparison with group Q, IVUS demonstrated slightly smaller PA and %AS in group A immediately after stenting in the site of the proximal vessel that was used as a reference against the stenting site. This could have influenced the changes in NA in the follow-up phase. Instead of providing a control group, group A and group Q were used for comparison in this study for the purpose of eliminating the BP factor, and the results obtained suggested more benefit in group A than in group Q. However, it will be necessary to conduct a prospective control study to investigate the extent of inhibitory activity in group A alone. Although opinions are still divided concerning the prophylactic efficacy of quinapril against in-stent restenosis, this study demonstrated the superiority of amlodipine to quinapril on the basis of QCA and IVUS findings.
Inhibition of hyperplasia and the wandering of vascular smooth muscle have been reported as mechanisms of the anti-atherosclerotic properties of amlodipine. [12] [13] [14] Komatsu et al reported on highly advanced neointimal hyperplasia in in-stent restenosis as well as the concentric hyperplasia of neocapillaries and marked aggregation of macrophages in the neointimal deep layer, suggesting that subsequent excessive wandering and hyperplasia of smooth muscle cells are caused by platelet-derived growth factor (PDGF) and other growth factors produced by macrophages. 15 The results of this study suggest that amlodipine inhibits neointimal hyperplasia after stenting. This inhibition is assumed to be due to an effect on vascular smooth muscle.
Concerning the prophylactic efficacy of other drugs against in-stent restenosis, the anti-hyperlipidemia drug probucol is reported to be effective, 16 but further investigation of its safety is necessary. According to the recently reported results of a large-scale clinical study, the antiallergic drug tranilast demonstrated no inhibition of restenosis. 17 However, of interest is the result of the Val-PREST (Valsartan for prevention of restenosis after stenting of type B2/C lesions) study 18 of the prophylactic efficacy of the AT1 receptor antagonist valsartan. Furthermore, Wakeyama et al reported that after coronary stenting candesartan failed to inhibit the neointimal hyperplasia and although the combination with probucol treatment did reduce neointimal hyperplasia, it did not statistically reduce the restenosis rate. 19 Recently, drug eluting stents have attracted attention, 20, 21 but these new devices have unproven long-term efficacy and safety. Furthermore, these stents cannot be expected to inhibit the progression of overall coronary or systemic atherosclerosis because they are intended for local treatment. Therefore, treatment with amlodipine is believed to be more advantageous.
There are limitations to this study. The number of cases investigated in this study was small and, in particular, the number of IVUS cases was still smaller in part because IVUS was not performed in patients who had restenosis in the follow-up phase and because comparison was performed only for cases whose IVUS images both immediately after stenting and in the follow-up phase were clear and able to be analyzed. As it is not appropriate to draw conclusions simply on the basis of data obtained from these cases, it will be necessary to conduct another study with a larger number of cases. For the purpose of eliminating the BP factor, no control group was provided in this study, but it will also be necessary to conduct a prospective control study in the future.
Conclusion
QCA and IVUS findings suggested a beneficial effect of amlodipine compared with quinapril in inhibiting neointimal hyperplasia in sites of stenting.
